The Role of A New-Generation JAK inhibitor in The Treatment of Rheumatoid Arthritis
Chair: Prof Tsutomu Takeuchi
In this symposium, we will explore the clinical efficacy of Filgotinib in the treatment of rheumatoid arthritis, including prevention of structural joint damage and its safety profile, based on the results of pivotal clinical data. In addition, we will provide a comprehensive review of herpes zoster which require careful attention when using JAK inhibitors and explore the potential of Filgotinib
The Role of A New-Generation JAK inhibitor in The Treatment of Rheumatoid Arthritis.
Dr Mitsumasa Kishimoto (Japan)